-
Ligand Pharma (LGND) PT Raised to $230 at Stifel
-
Citi Starts Ligand Pharma (LGND) at Buy
-
RBC Capital Reiterates Outperform Rating on Ligand Pharma (LGND), Investor Day Preview
-
Ligand Pharma (LGND) PT Raised to $234 at RBC Capital
-
Pelthos Therapeutics acquires Xepi cream and raises $18 million
-
Ligand Pharma (LGND) PT Raised to $220 at Stifel
-
Ligand Pharma (LGND) Tops Q3 EPS by 116c ; Offers Guidance
-
Ligand Pharma (LGND) PT Raised to $190 at Oppenheimer
-
Ligand Pharma (LGND) PT Raised to $175 at Benchmark
-
Ligand Pharma (LGND) PT Raised to $206 at H.C. Wainwright
-
Ligand Pharma (LGND) PT Raised to $160 at Benchmark On Model Adjustment
-
Ligand Pharma (LGND) PT Raised to $185 at RBC Capital
-
Ligand Pharma (LGND) PT Raised to $167 at Oppenheimer
-
Ligand Pharma (LGND) Tops Q2 EPS by 17c ; Offers Guidance
-
Orchestra BioMed raises $111 million through equity offerings and partnerships
-
Ligand and Medtronic invest $70 million in Orchestra BioMed
-
Ligand Pharma (LGND) PT Raised to $162 at Oppenheimer
-
Stifel Reiterates Buy Rating on Ligand Pharma (LGND)
-
Ligand earns $5 million milestone as partner launches molluscum drug
-
Stifel: 'MRK Acquisition of VRNA Should Broaden Opportunity for Ohtuvayre – A Core LGND Growth Driver'
-
Ligand Pharma (LGND) Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
-
Ligand Pharma (LGND) Tops Q1 EPS by 11c ; Offers Guidance
-
Stifel Starts Ligand Pharma (LGND) at Buy
-
Ligand Pharma (LGND) PT Raised to $153 at RBC Capital Following a 'Strong Quarter'
-
Ligand Pharma (LGND) Tops Q4 EPS by 9c ; Offers Guidance
-
Ligand Pharma (LGND) Leads $75 Million Royalty Financing in Castle Creek Biosciences
-
Benchmark on Ligand Pharma (LGND): '2025 Expected to Follow 2024 with Strong Revenue Growth'
-
Ligand Pharma (LGND) PT Raised to $143 at RBC Capital
-
Ligand Pharma (LGND) PT Raised to $150 at Oppenheimer
-
Ligand Pharma (LGND) Introduces 2025 Guidance
-
Ligand Pharma (LGND) PT Raised to $141 at RBC Capital Ahead of Investor Day
-
Ligand Pharma (LGND) Tops Q3 EPS by 50c ; Offers Guidance
-
Ligand Pharma (LGND) PT Raised to $157 at H.C. Wainwright
-
RBC Capital Starts Ligand Pharma (LGND) at Outperform
-
Pieris Pharma (PIRS) and Palvella Therapeutics to Merge
-
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
-
Ligand Pharma (LGND) PT Raised to $140 at Craig-Hallum
-
Ligand Pharma (LGND) to Buy Apeiron Biologics for $100M Cash
-
H.C. Wainwright Reiterates Buy Rating on Ligand Pharma (LGND)
-
Ligand Pharma (LGND) Verona Pharma Announces FDA Approval of Ohtuvayre, First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

